Fight Aging!

Stem cell therapies involve a stage of expansion of cells in culture prior to injecting them into the patient. The research community has realized that both the state of the original source cells and small variations in the subsequent cell culture environment can result in large differences in the quality of the transplanted cells. For example, how many of the cells in the culture have become senescent, and are thus now generating pro-inflammatory signals. There are other possible variations in cell state that could contribute negatively to outcomes, diminishing any benefits resulting from the therapy, however. Differences in cell state and behavior may be the cause of much of the well-known and undesirable variability of outcomes in stem cell therapy.

Some clinics may have started to at least attempt to use senolytic treatments to reduce the number of senescent cells in stem cell cultures, but this is by no means yet a standard. Today's open access paper discusses this issue, expanding the consideration from senescent cells to other problematic changes in cell state that may negatively impact outcomes for patients. They present this as a quality issue, discoveries to be added to the consensus on what constitutes Good Manufacturing Practice (GMP) for stem cell therapies provided within more regulated regions of the world. Medical tourism of course remains a black box in this as in many other matters.

Proteotoxic stress in stem cell therapies: The overlooked roles of senescence, EV cargo, and SOD1

The rapid clinical expansion of therapies based on stem cells and cell-free extracellular vesicles (EVs) has outpaced the development of rigorous quality control standards. Current Good Manufacturing Practice (GMP) standards evaluate identity, viability, sterility, and genetic stability, but do not routinely assess protein homeostasis in donor cells. Cellular senescence, which frequently emerges during ex vivo expansion, impairs protein quality control and yields an EV secretome enriched with proteotoxic cargo. In neural stem cells (NSCs), oxidized superoxide dismutase 1 (SOD1) accumulates during senescence and is packaged into EVs that propagate neuronal toxicity and secondary senescence in recipient cells.

While established primarily in NSCs, analogous proteostatic decline across other stem cell types warrants targeted validation in mesenchymal stromal cell (MSC) and induced pluripotent stem cell (iPSC)-derived products. Donor cell proteostatic fitness is a plausible determinant of therapeutic outcome. Evaluating senescence burden and EV proteomic integrity should therefore become a standard critical quality attribute within cell and EV manufacturing pipelines. Practical steps toward this goal include the careful selection of cell sources, the establishment of quantitative senescence thresholds, and proteomic profiling of EV cargo. Targeted cargo sanitization strategies, such as selective clearance of misfolded SOD1, shows promise for pre-transplant conditioning, although clinical feasibility, scalability, and off-target effects require further study.